NOVACYT (ALNOV.PA) Stock Fundamental Analysis

EPA:ALNOV • FR0010397232

0.399 EUR
+0 (+0.5%)
Last: Feb 18, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ALNOV. ALNOV was compared to 78 industry peers in the Biotechnology industry. The financial health of ALNOV is average, but there are quite some concerns on its profitability. ALNOV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year ALNOV has reported negative net income.
  • In the past year ALNOV has reported a negative cash flow from operations.
  • In the past 5 years ALNOV reported 4 times negative net income.
  • In multiple years ALNOV reported negative operating cash flow during the last 5 years.
ALNOV.PA Yearly Net Income VS EBIT VS OCF VS FCFALNOV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

1.2 Ratios

  • ALNOV has a Return On Assets (-48.32%) which is in line with its industry peers.
  • ALNOV has a Return On Equity of -74.44%. This is comparable to the rest of the industry: ALNOV outperforms 57.69% of its industry peers.
Industry RankSector Rank
ROA -48.32%
ROE -74.44%
ROIC N/A
ROA(3y)-32.84%
ROA(5y)-9.46%
ROE(3y)-47.33%
ROE(5y)-12.19%
ROIC(3y)N/A
ROIC(5y)N/A
ALNOV.PA Yearly ROA, ROE, ROICALNOV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

  • ALNOV's Gross Margin of 63.35% is in line compared to the rest of the industry. ALNOV outperforms 57.69% of its industry peers.
  • In the last couple of years the Gross Margin of ALNOV has grown nicely.
  • The Profit Margin and Operating Margin are not available for ALNOV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y75.01%
GM growth 5Y20.62%
ALNOV.PA Yearly Profit, Operating, Gross MarginsALNOV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • ALNOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ALNOV remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for ALNOV has been increased compared to 5 years ago.
  • The debt/assets ratio for ALNOV is higher compared to a year ago.
ALNOV.PA Yearly Shares OutstandingALNOV.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ALNOV.PA Yearly Total Debt VS Total AssetsALNOV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • ALNOV has an Altman-Z score of 0.46. This is a bad value and indicates that ALNOV is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of 0.46, ALNOV perfoms like the industry average, outperforming 56.41% of the companies in the same industry.
  • A Debt/Equity ratio of 0.24 indicates that ALNOV is not too dependend on debt financing.
  • ALNOV has a Debt to Equity ratio of 0.24. This is in the better half of the industry: ALNOV outperforms 61.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Altman-Z 0.46
ROIC/WACCN/A
WACC6.76%
ALNOV.PA Yearly LT Debt VS Equity VS FCFALNOV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • ALNOV has a Current Ratio of 5.03. This indicates that ALNOV is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of ALNOV (5.03) is better than 80.77% of its industry peers.
  • ALNOV has a Quick Ratio of 4.59. This indicates that ALNOV is financially healthy and has no problem in meeting its short term obligations.
  • ALNOV has a Quick ratio of 4.59. This is amongst the best in the industry. ALNOV outperforms 80.77% of its industry peers.
Industry RankSector Rank
Current Ratio 5.03
Quick Ratio 4.59
ALNOV.PA Yearly Current Assets VS Current LiabilitesALNOV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 17.85% over the past year.
  • Looking at the last year, ALNOV shows a quite strong growth in Revenue. The Revenue has grown by 8.50% in the last year.
  • Measured over the past years, ALNOV shows a quite strong growth in Revenue. The Revenue has been growing by 11.35% on average per year.
EPS 1Y (TTM)17.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.73%
Revenue 1Y (TTM)8.5%
Revenue growth 3Y-40.37%
Revenue growth 5Y11.35%
Sales Q2Q%-5.12%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALNOV.PA Yearly Revenue VS EstimatesALNOV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
ALNOV.PA Yearly EPS VS EstimatesALNOV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2020 2021 2022 2023 2024 0 0.5 -0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • ALNOV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALNOV.PA Price Earnings VS Forward Price EarningsALNOV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALNOV.PA Per share dataALNOV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ALNOV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NOVACYT

EPA:ALNOV (2/18/2026, 7:00:00 PM)

0.399

+0 (+0.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-21
Earnings (Next)N/A
Inst Owners0.05%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap28.18M
Revenue(TTM)19.10M
Net Income(TTM)-30.40M
Analysts37.14
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.29
P/FCF N/A
P/OCF N/A
P/B 0.6
P/tB 1.13
EV/EBITDA N/A
EPS(TTM)-0.5
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.31
BVpS0.66
TBVpS0.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.32%
ROE -74.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.35%
FCFM N/A
ROA(3y)-32.84%
ROA(5y)-9.46%
ROE(3y)-47.33%
ROE(5y)-12.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y75.01%
GM growth 5Y20.62%
F-Score4
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 8.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.03
Quick Ratio 4.59
Altman-Z 0.46
F-Score4
WACC6.76%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.93%
Cap/Sales(5y)4.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.73%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)8.5%
Revenue growth 3Y-40.37%
Revenue growth 5Y11.35%
Sales Q2Q%-5.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.03%
OCF growth 3YN/A
OCF growth 5YN/A

NOVACYT / ALNOV.PA FAQ

What is the ChartMill fundamental rating of NOVACYT (ALNOV.PA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ALNOV.PA.


Can you provide the valuation status for NOVACYT?

ChartMill assigns a valuation rating of 0 / 10 to NOVACYT (ALNOV.PA). This can be considered as Overvalued.


Can you provide the profitability details for NOVACYT?

NOVACYT (ALNOV.PA) has a profitability rating of 2 / 10.


What is the financial health of NOVACYT (ALNOV.PA) stock?

The financial health rating of NOVACYT (ALNOV.PA) is 5 / 10.